Breaking News Instant updates and real-time market news.

NBRV

Nabriva Therapeutics

$2.31

-0.09 (-3.75%)

07:04
11/06/18
11/06
07:04
11/06/18
07:04

Nabriva Therapeutics reports Q3 EPS (90c), consensus (29c)

Reports Q3 revenue $1.468M, consensus $2.3M.

  • 27

    Nov

NBRV Nabriva Therapeutics
$2.31

-0.09 (-3.75%)

05/31/18
CANT
05/31/18
NO CHANGE
Target $16
CANT
Overweight
Nabriva Therapeutics valuation 'hard to resist,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says she left meetings with Nabriva Therapeutics management even more convinced that the market opportunity for lefamulin is underappreciated. Nabriva Therapeutics shares have been weak since the company announced positive data from its second Phase 3 study, Chen tells investors in a research note titled "NBRV Hard to Resist At Its Current Valuation." She sees no fundamental reason for the weakness and keeps an Overweight rating on the shares with a $16 price target.
05/31/18
NORL
05/31/18
INITIATION
Target $17.5
NORL
Outperform
Nabriva Therapeutics initiated with an Outperform at Northland
Northland initiated Nabriva Therapeutics with an Outperform and $17.50 price target.
08/27/18
BOFA
08/27/18
NO CHANGE
Target $5
BOFA
Buy
Nabriva Therapeutics price target lowered to $5 from $9 at BofA/Merrill
BofA/Merrill analyst Jason Gerberry lowered his price target on Nabriva Therapeutics to $5, citing his lower expected probability of success of 60% vs. 75% prior in its recently acquired CONTEPO for complicated urinary tract infection. The analyst says the program's main risk is an "imbalance of liver enzyme elevation while a slightly higher dose reduces read -through from about a 45-year post-market EU safety". Gerberry now believes that CONTEPO is a "niche opportunity", and lowers his peak sales view to $50M from $80M prior. The analyst also keeps his Buy rating on Nabriva on valuation as well as the opportunity for its two FDA action dates for lefamulin and CONTEPO in the second half of 2019.
09/07/18
MSCO
09/07/18
INITIATION
Target $8
MSCO
Overweight
Nabriva Therapeutics resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of Nabriva Therapeutics with an Overweight rating and a $8 price target, stating that its "first-in-class" antibiotics lefamulin and Contepo both have approvable Phase 3 data. He believes at current levels Nabriva shares are pricing in a "worst case scenario" for both antibiotics, but he sees it as likely that Nabriva exceeds the low expectations. Lebowitz forecasts risk-adjusted 2025 sales for lefamulin and Contepo of $228M and $33M, respectively.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.